Tag:
Phase II
Latest Headlines
Latest Headlines
Developers find that Phase II hurdle is getting harder to clear
Phase II has long represented the key crossroads for a biotech company. Getting a promising outcome is a good way to earn a lucrative partnering deal, possibly even a buyout. But a new analysis shows
Xoma shares blitzed after lead drug flunks key diabetes study
Xoma's lead drug failed a Phase IIb diabetes study and news of the debacle quickly sent its stock into a tailspin, wiping out 37% of the biotech's market value in minutes yesterday evening. The trial
Struggling XenoPort shelves GERD program after Ph2b failure
XenoPort is shelving one of its two development programs for arbaclofen placarbil after its Phase IIb heartburn study failed to demonstrate a clear benefit over a sugar pill. Researchers had been
Pfizer's tasocitinib for psoriasis shows Phase II promise
Pfizer is touting results from a Phase II trial of tasocitinib (CP-690,550), an oral JAK inhibitor for moderate to severe plaque psoriasis. The drug is designed to block enzymes that play a key role
Ardea shares spike on promising PhIIb gout drug data
Shares of Ardea Biosciences (RDEA) surged 23 percent in after-market trading yesterday evening after the developer posted positive data for its dose-ranging, mid-stage trial of its experimental gout
J&J's prostate cancer drug proves promising in Ph2
A mid-stage trial for abiraterone--an oral drug which inspired a billion-dollar buyout less than a year ago--has produced another set of promising results for men with advanced, treatment-resistant
Geron stem cell therapy promising in the lab
An experimental stem cell therapy in Geron's pipeline produced some promising preclinical results for glioblastoma brain cancer and prostate cancer. Researchers say that imetelstat (also called
Icagen shares plunge on failed asthma trial
Icagen's share price was battered this morning after the develop announced that it is shelving its experimental asthma drug, senicapoc, after it failed a mid-stage trial. Icagen shares plunged 42
Oxford BioMedica surges on Parkinson's trial success
Following hot on the heels of Phytopharm's announcement yesterday that its Parkinson's treatment had delivered promising results in animal and human studies, Oxford BioMedica thrilled analysts with a
Promising pain data fuels spike in XenoPort shares
Shares of XenoPort barreled ahead 29 percent on Thursday after researchers reported that its neuropathic pain drug--which is partnered with GlaxoSmithKline--hit its primary endpoint of reducing the
- « first
- ‹ previous
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- …
- next ›
- last »
